This Article Full Text Full Text (PDF) All Versions of this Article: 45/2/163    most recent 01.HYP.0000153321.13792.b9v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Watanabe, T. Articles by Berk, B. C. Search for Related Content PubMed PubMed Citation Articles by Watanabe, T. Articles by Berk, B. C. Related Collections Signal transduction Endothelium/vascular type/nitric oxide

(Hypertension. 2005;45:163.)
© 2005 American Heart Association, Inc.

Brief Review

Angiotensin II and the Endothelium

Diverse Signals and Effects

From the Center for Cardiovascular Research, University of Rochester, New York.

Correspondence to Bradford C. Berk, MD, PhD, Center for Cardiovascular Research, University of Rochester, Box 679, 601 Elmwood Ave, Rochester, NY 14642. E-mail bradford_berk{at}urmc.rochester.edu

The initial view of the renin-angiotensin system focused on the role of angiotensin II as a hormone involved in blood pressure control, based on its role in renal salt and water regulation, as well as central nervous system (thirst) and vascular smooth muscle tone. Subsequent data showed a role for angiotensin II in long-term effects on cardiovascular structure, including cardiac hypertrophy and vascular remodeling. Importantly, recent human studies with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers have demonstrated exciting clinical benefits including decreases in incidence of stroke, diabetes, and end-stage renal disease that suggest important new mechanisms of action. In this review, we focus on new roles for the renin-angiotensin system in the endothelium based on the concepts of diverse signals and effects mediated by multiple angiotensin I- and angiotensin II-derived peptides, multiple angiotensin metabolizing enzymes, multiple receptors, and vascular bed-specific intracellular signals.

Key Words: angiotensin II • endothelium • signal transduction

This article has been cited by other articles:

				N. Y. Tan, J.-M. Li, R. Stocker, and L. M. Khachigian Angiotensin II-Inducible Smooth Muscle Cell Apoptosis Involves the Angiotensin II Type 2 Receptor, GATA-6 Activation, and FasL-Fas Engagement Circ. Res., August 28, 2009; 105(5): 422 - 430. [Abstract] [Full Text] [PDF]

				Y. Ochiai, Y.-Q. Liang, M. Serizawa, and N. Kato Dynamic changes of the renin-angiotensin and associated systems in the rat after pharmacological and dietary interventions in vivo Physiol Genomics, November 12, 2008; 35(3): 330 - 340. [Abstract] [Full Text] [PDF]

				J. Pang, C. Yan, K. Natarajan, M. E. Cavet, M. P. Massett, G. Yin, and B. C. Berk GIT1 Mediates HDAC5 Activation by Angiotensin II in Vascular Smooth Muscle Cells Arterioscler Thromb Vasc Biol, May 1, 2008; 28(5): 892 - 898. [Abstract] [Full Text] [PDF]

				N. Y. Tan, V. C. Midgley, M. M. Kavurma, F. S. Santiago, X. Luo, R. Peden, R. G. Fahmy, M. C. Berndt, M. P. Molloy, and L. M. Khachigian Angiotensin II-Inducible Platelet-Derived Growth Factor-D Transcription Requires Specific Ser/Thr Residues in the Second Zinc Finger Region of Sp1 Circ. Res., February 29, 2008; 102(4): e38 - e51. [Abstract] [Full Text] [PDF]

				S. Brili, D. Tousoulis, C. Antoniades, C. Vasiliadou, M. Karali, N. Papageorgiou, N. Ioakeimidis, K. Marinou, E. Stefanadi, and C. Stefanadis Effects of Ramipril on Endothelial Function and the Expression of Proinflammatory Cytokines and Adhesion Molecules in Young Normotensive Subjects With Successfully Repaired Coarctation of Aorta A Randomized Cross-Over Study. J. Am. Coll. Cardiol., February 19, 2008; 51(7): 742 - 749. [Abstract] [Full Text] [PDF]

				F. Helle, O. B. Vagnes, and B. M. Iversen Angiotensin II-induced calcium signaling in the afferent arteriole from rats with two-kidney, one-clip hypertension Am J Physiol Renal Physiol, July 1, 2006; 291(1): F140 - F147. [Abstract] [Full Text] [PDF]

				N. A.J. van der Linde, E. J.G. Sijbrands, F. Boomsma, and A. H. van den Meiracker Effect of Low-Density Lipoprotein Cholesterol on Angiotensin II Sensitivity: A Randomized Trial With Fluvastatin Hypertension, June 1, 2006; 47(6): 1125 - 1130. [Abstract] [Full Text] [PDF]

				I. F. Benter, M. H. M. Yousif, J. T. Anim, C. Cojocel, and D. I. Diz Angiotensin-(1-7) prevents development of severe hypertension and end-organ damage in spontaneously hypertensive rats treated with L-NAME Am J Physiol Heart Circ Physiol, February 1, 2006; 290(2): H684 - H691. [Abstract] [Full Text] [PDF]

				V. L. M. Herrera, L. R. B. Ponce, P. D. Bagamasbad, B. D. VanPelt, T. Didishvili, and N. Ruiz-Opazo Embryonic lethality in Dear gene-deficient mice: new player in angiogenesis Physiol Genomics, November 17, 2005; 23(3): 257 - 268. [Abstract] [Full Text] [PDF]

				T. E. Strandberg Editorial Comment: Secondary Prevention of Stroke Is Important: But All Hypertensive Drugs Are Not Created Equal? Stroke, June 1, 2005; 36(6): 1225 - 1226. [Full Text] [PDF]

				B. C. Blaxall, J. M. Miano, and B. C. Berk Angiotensin II: A Devious Activator of Mineralocorticoid Receptor-Dependent Gene Expression Circ. Res., April 1, 2005; 96(6): 610 - 611. [Full Text] [PDF]